Michael Megna Sells 4,600 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CAO Michael Megna sold 4,600 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total value of $369,380.00. Following the sale, the chief accounting officer directly owned 29,062 shares in the company, valued at $2,333,678.60. The trade was a 13.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ KNSA opened at $77.91 on Friday. The firm has a 50 day moving average price of $71.98 and a two-hundred day moving average price of $57.36. The stock has a market cap of $6.08 billion, a P/E ratio of 80.32 and a beta of 0.09. Kiniksa Pharmaceuticals International, plc has a 52-week low of $35.12 and a 52-week high of $82.94.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, hitting analysts’ consensus estimates of $0.30. The company had revenue of $243.60 million for the quarter, compared to analyst estimates of $226.49 million. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. Analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.37 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in shares of Kiniksa Pharmaceuticals International by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock valued at $128,409,000 after acquiring an additional 49,802 shares in the last quarter. UBS Group AG boosted its stake in Kiniksa Pharmaceuticals International by 56.4% during the fourth quarter. UBS Group AG now owns 77,916 shares of the company’s stock worth $3,214,000 after acquiring an additional 28,099 shares in the last quarter. Inspire Investing LLC acquired a new stake in Kiniksa Pharmaceuticals International in the first quarter worth $1,698,000. BNP Paribas Financial Markets grew its holdings in Kiniksa Pharmaceuticals International by 27.3% in the fourth quarter. BNP Paribas Financial Markets now owns 831,777 shares of the company’s stock worth $34,311,000 after purchasing an additional 178,366 shares during the period. Finally, SG Americas Securities LLC increased its stake in Kiniksa Pharmaceuticals International by 18.2% in the first quarter. SG Americas Securities LLC now owns 640,179 shares of the company’s stock valued at $30,825,000 after purchasing an additional 98,783 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on KNSA. The Goldman Sachs Group increased their price target on Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Wedbush upped their target price on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. Weiss Ratings downgraded shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, August 13th. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 12th. Finally, Citigroup boosted their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Eight analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $87.38.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.